The First Affiliated Hospital Chongqing Medical University
Welcome,         Profile    Billing    Logout  
 19 Trials 
10 Trials

   Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Li, Qifu
NCT06738979: A Clinical Study Comparing Semaglutide Injection and Wegovy® for Weight Management in Obese Subjects

Not yet recruiting
3
408
RoW
TQF3510 (Semaglutide Injection), Wegovy®
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Obesity
07/26
08/26
TQF2409-III-01, NCT04955834: A Clinical Study of Insulin Degludec Injection in Subjects With Type 2 Diabetes

Recruiting
3
344
RoW
Insulin degludec injection, Tresiba®
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Type 2 Diabetes
12/25
12/25
Li, Fan
EMBER-4, NCT05514054: A Study of Imlunestrant Versus Standard Endocrine Therapy in Participants With Early Breast Cancer

Recruiting
3
6000
Europe, Canada, Japan, US, RoW
Imlunestrant, LY3484356, Tamoxifen, Anastrozole, Letrozole, Exemestane
Eli Lilly and Company
Breast Neoplasms
10/27
03/32
Zhu, Yuxi
TQB2450-III-05, NCT04325763: A Study of TQB2450 in Subjects With Stage III Non-Small Cell Lung Cancer(NSCLC)

Recruiting
3
315
RoW
TQB2450, Anlotinib, TQB2450(blank), Anlotinib(blank)
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Stage III Non-small-cell Lung Cancer
12/22
03/25
Gou, Xin
NCT04691804 / 2020-006063-28: A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase III Study of Fuzuloparib Combined With Abiraterone Acetate and Prednisone (AA-P) Versus Placebo Combined With AA-P as First-Line Treatment in Patients With Metastatic Castration-Resistant Prostate Cancer

Active, not recruiting
3
496
Europe, US, RoW
Fuzuloparib , Abiraterone acetate and Prednisone, SHR3162, Fuzuloparib Placebo， Abiraterone acetate and Prednisone
Jiangsu HengRui Medicine Co., Ltd.
Metastatic Castration-Resistant Prostate Cancer (mCRPC)
12/26
12/26
NCT04738630: Study of HX008 for the Treatment of BCG-Unresponsive Non-muscle Invasive Bladder Cancer

Recruiting
2
110
RoW
HX008
Taizhou Hanzhong biomedical co. LTD
Bladder Cancer
12/22
12/23
He, Weiyang
CYCLONE 3, NCT05288166: A Study of Abemaciclib (LY2835219) With Abiraterone in Men With Prostate Cancer That Has Spread to Other Parts of the Body and is Expected to Respond to Hormonal Treatment (Metastatic Hormone-Sensitive Prostate Cancer)

Active, not recruiting
3
900
Europe, Canada, Japan, US, RoW
Abemaciclib, LY2835219, Abiraterone, Prednisone or Prednisolone, Placebo for Abemaciclib
Eli Lilly and Company
Prostatic Neoplasms, Neoplasm Metastasis, Urogenital Neoplasms, Physiological Effects of Drugs, Antineoplastic Agents, Antineoplastic Agents, Hormonal, Androgens, Hormones, Hormones, Hormone Substitutes, and Hormone Antagonists, Abiraterone Acetate, Steroid Synthesis Inhibitors, Cytochrome P-450, Enzyme Inhibitors, Prednisone, Prednisolone, Cyclin-Dependent Kinase 4, Cyclin-Dependent Kinase 6
02/24
10/27
NCT04492293: An Efficacy and Safety Study of ICP-192 in Subjects With Bladder Urothelial Cancer

Recruiting
2
115
RoW
ICP-192
Beijing InnoCare Pharma Tech Co., Ltd.
Bladder Urothelial Cancer
12/24
06/25
Cheng, Oumei
NCT05181475: Long-term Efficacy and Safety Study of GV-971

Active, not recruiting
4
800
RoW
Sodium Oligomannate Capsules (GV-971)
Green Valley (Shanghai) Pharmaceuticals Co., Ltd.
Alzheimer Disease
01/25
06/25
TRAILBLAZER-ALZ 5, NCT05508789: A Study of Donanemab (LY3002813) in Participants With Early Symptomatic Alzheimer's Disease

Recruiting
3
1500
Europe, RoW
Donanemab, (LY3002813), Placebo
Eli Lilly and Company
Alzheimer Disease, Dementia, Brain Diseases, Central Nervous System Diseases, Nervous System Diseases, Tauopathies, Neurodegenerative Diseases, Neurocognitive Disorders, Mental Disorders
04/27
04/27

Download Options